• Abeona Therapeutics CFO Joseph Walter Vazzano sold 49,338 common shares on June 8-9, 2026 at weighted-average prices near USD 5.30-5.43.
• Holdings fell to 518,437 shares following the transactions.
• Sales included tax-withholding related dispositions tied to restricted stock vesting.
• Part of the June 9 sale was executed under a Rule 10b5-1 plan adopted Jan. 21, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-028022), on June 09, 2026, and is solely responsible for the information contained therein.